Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)

Eunae Sandra Cho(Royal Prince Alfred Hospital), Levon M. Khachigian(Prince of Wales Hospital), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Hong Cai(Shanghai Medical College of Fudan University), Diona L. Damian(The University of Sydney), Douglas J. Francis(Services Australia), Benafsha Yosufi(Melanoma Institute Australia), Paula T. Hammond(Broad Institute), Richard A. Scolyer(The University of Sydney), Carlos China(Woolcock Institute of Medical Research), Gary M. Halliday(University of Sydney), Fergal J. Moloney(Royal Prince Alfred Hospital), Stephen W. Morton(Massachusetts Institute of Technology), Jason Z. Deng(Massachusetts Institute of Technology), Ross St.C. Barnetson(Royal Prince Alfred Hospital), Mark J. Raftery(UNSW Sydney), Colin N. Chesterman(UNSW Sydney), Annie Au-Yeung(UNSW Sydney)
The Lancet
May 1, 2013
Cited by 107


Related Papers